Gene markers and antihypertensive therapy

Current Hypertension Reports

Volumn 7, Issue 1, 2005, Pages 21-30

  Turner, Stephen T ^a   Schwartz, Gary L ^a  

^a Mayo Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BENAZEPRIL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CAPTOPRIL; CLONIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; FOSINOPRIL; FUROSEMIDE; HYDROCHLOROTHIAZIDE; IMIDAPRIL; IRBESARTAN; LOSARTAN; METOPROLOL; NIFEDIPINE; PERINDOPRIL; RAMIPRIL;

ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; DRUG CHOICE; DRUG RESPONSE; ENVIRONMENTAL FACTOR; GENE INTERACTION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; HYPERTENSION; MARKER GENE; PRACTICE GUIDELINE; PREDICTION; REVIEW; SAMPLE SIZE;

EID: 14044257846     PISSN: 15226417     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11906-005-0051-y     Document Type: Review

References (58)

1. Bianchi G: Pharmacogenomics and genetics of primary hypertension. Curr Hypertens Rep 2001, 3:441-443.
2. Cooper RS, Psaty BM: Genomics and medicine: distraction, incremental progress, or the dawn of a new age? Ann Intern Med 2003, 138:576-580.
3. Turner ST, Schwartz GL, Chapman AB, Boerwinkle E: Use of gene markers to guide antihypertensive therapy. Curr Hypertens Rep 2001, 3:410-415.
4. Finkielman JD, Schwartz GL, Chapman AB, et al.: Reproducibility of blood pressure response to hydrochlorothiazide. J Clin Hypertens (Greenwich) 2002, 4:408-412.
5. Daniels PR, Kardia SLR, Hanis CL, et al.: Familial aggregation of hypertension treatment and control in the GENOA study. Am J Med 2004, 116:676-681.
6. Vogel F: Moderne probleme der Humangenetik. Ergebn Inn Med Kinderheilk 1959, 12:52-125.
7. Weber WW: Pharmacogenetics, vol 32, edn 2. Oxford, New York: Oxford University Press; 1997.
8. Hollenberg NK, Anzalone DA, Falkner B, et al.: Familial factors in the antihypertensive response to lisinopril. Am J Hypertens 2001, 14:218-223.
9. Laragh JH, Lamport B, Sealey J, Alderman MH: Diagnosis ex juvantibus: individual response patterns to drugs reveal hypertension mechanisms and simplify treatment. Hypertension 1988, 12: 23-226.
10. Cusi D, Barlassina C, Azzani T, et al.: Polymorphisms of alpha-adducin and salt sensitivity in patients with essential hypertension. Lancet 1997, 349:1353-1357.
11. Glorioso N, Manunta P, Filigheddu F, et al.: The role of alpha-adducin polymorphism in blood pressure and sodium handling regulation may not be excluded by a negative association study. Hypertension 1999, 34(4 Pt 1):649-654.
12. Rigat B, Hubert C, Alhenc-Gelas F, et al.: An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 1990, 86:1343-1346.
13. Sciarrone MT, Stella P, Barlassina C, et al.: ACE and alpha-adducin polymorphism as markers of individual response to diuretic therapy. Hypertension 2003, 41:398-403.
14. Manunta F, Cusi D, Barlassina C, et al.: Alpha-adducin polymorphisms and renal sodium handling in essential hypertensive patients. Kidney Int 1998, 53:1471-1478.
15. Grant FD, Romero JR, Jeunemaitre X, et al.: Low-renin hypertension, altered sodium homeostasis, and an alpha-adducin polymorphism. Hypertension 2002, 39:191-196.
16. Kojima S, Inenaga T, Matsuoka H, et al.: The association between salt sensitivity of blood pressure and some polymorphic factors. J Hypertens 1994, 12:797-801.
17. Turner ST, Schwartz GL, Chapman AB, Boerwinkle E: C825T polymorphism of the G protein beta(3)-subunit and antihypertensive response to a thiazide diuretic. Hypertension 2001, 37(2 Pt 2):739-743.
18. Schunkert H, Hense HW, Doting A, et al.: Association between a polymorphism in the G protein beta3 subunit gene and lower renin and elevated diastolic blood pressure levels. Hypertension 1998, 32:510-513.
19. Siffert W: G protein beta 3 subunit 825T allele, hypertension, obesity, and diabetic nephropathy. Nephrol Dial Transplant 2000, 15:1298-1306.
20. Schwartz GL, Turner ST, Chapman AB, Boerwinkle E: Interacting effects of gender and genotype on blood pressure response to hydrochlorothiazide. Kidney Int 2002, 62:1718-1723.
21. Turner S, Boerwinkle E, Sing C: Context-dependent associations of the ACE I/D polymorphism with blood pressure. Hypertension 1999, 34:773-778.
22. Fornage M, Amos CI, Kardia S, et al.: Variation in the region of the angiotensin-converting enzyme gene influences inter-individual differences in blood pressure levels in young white males. Circulation 1998, 97:1773-1779.
23. O'Donnell CJ, Lindpaintner K, Larson MG, et al.: Evidence for association and genetic linkage of the angiotensin-converting enzyme locus with hypertension and blood pressure in men but not women in the Framingham Heart Study. Circulation 1998, 97:1766-1772.
24. Turner ST, Chapman AB, Schwartz GL, Boerwinkle E: Effects of endothelial nitric oxide synthase, alpha adducin, and other candidate gene polymorphisms on blood pressure response to hydrochlorothiazide. Am J Hypertens 2003, 16:834-839.
25. Frazier L, Turner ST, Schwartz GL, et al.: Multilocus effects of the renin-angiotensin-aldosterone system genes on blood pressure response to a thiazide diuretic. Pharmacogenomics J 2004, 4:17-23.
26. Johnson JA, Zineh I, Puckett BJ, et al.: Beta 1-adrenergic receptor polymorphisms and antihypertensive response to metoprolol. Clin Pharmacol Therap 2003, 74:44-52.
27. Kurland L, Melhus H, Karlsson I, et al.: Angiotensin converting enzyme gene polymorphism predicts blood pressure response to angiotensin II receptor type 1 antagonist treatment in hypertensive patients. J Hypertens 2001, 19:1783-1787.
28. Kurland L, Melhus H, Karlsson J, et al.: Aldosterone synthase (CYP11B2) -344 C/T polymorphism is related to antihypertensive response: result from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SIL-VHIA) trial. Am J Hypertens 2002, 15:389-393.
29. Progress Collaborative Group: Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001, 358:1033-1041.
30. Bonnardeaux A, Davies E, Jeunemaitre X, et al.: Angiotensin II type 1 receptor gene polymorphisms in human essential hypertension. Hypertension 1994, 24:63-69.
31. Benetos A, Gautier S, Ricard S, et al.: Influence of angiotensin-converting enzyme and angiotensin II type 1 receptor gene polymorphisms on aortic stiffness in normotensive and hypertensive patients. Circulation 1996, 94:698-703.
32. Miller JA, Thai K, Scholey JW: Angiotensin II type 1 receptor gene polymorphism predicts response to losartan and angiotensin II. Kidney Int 1999, 56:2173-2180.
33. Inoue I, Nakajima T, Williams CS, et al.: A nucleotide substitution in the promoter of human angiotensinogen is associated with essential hypertension and affects basal transcription in vitro. J Clin Invest 1997, 99:1786-1797.
34. Grossman E, Peleg E, Carroll J, et al.: Hemodynamic and Immoral effects of the angiotensin II antagonist losartan in essential hypertension. Am J Hypertens 1994, 7:1041-1044.
35. Davies E, Holloway CD, Ingram MC, et al.: Aldosterone excretion rate and blood pressure in essential hypertension are related to polymorphic differences in the aldosterone synthase gene CYP11B2. Hypertension 1999, 33:703-707.
36. Pojoga L, Gautier S, Blanc H, et al.: Genetic determination of plasma aldosterone levels in essential hypertension. Am J Hypertens 1998, 11:856-860.
37. Liljedahl U, Karlsson J, Melhus H, et al.: A microarray minisequencing system for pharmacogenetic profiling of antihypertensive drug response. Pharmacogenetics 2003, 13: -17.
38. Altmuller J, Palmer LJ, Fischer G, et al.: Genome-wide scans of complex human diseases: true linkage is hard to find. Am J Hum Genet 2001, 69:936-950.
39. Hoes AW, Grobbee DE, Lubsen J: Does drug treatment improve survival? Reconciling the trials in mild-to-moderate hypertension. J Hypertens 1995, 13:805-811.
40. Staessen JA, Byttebier G, Buntinx F, et al.: Antihypertensive treatment based on conventional or ambulatory blood pressure measurement: a randomized controlled trial. Ambulatory Blood Pressure Monitoring and Treatment of Hypertension Investigators. JAMA 1997, 278:1065-1072.
41. Dickerson JE, Hingorani AD, Ashby MJ, et al.: Optimisation of antihypertensive treatment by crossover rotation of four major classes. Lancet 1999, 353:2008-2013.
42. Psaty BM, Smith NL, Heckbert SR, et al.: Diuretic therapy, the alpha-adducin gene variant, and the risk of myocardial infarction or stroke in persons with treated hypertension. JAMA 2002, 287:1680-1689.
43. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002, 288: 981-2997.
44. Nurnberger J, Dammer S, Mitchell A, et al.: Effect of the C825T polymorphism of the G protein beta 3 subunit on the systolic blood pressure-lowering effect of clonidine in young, healthy male subjects. Clin Pharmacol Therap 2003, 74:53-60.
45. O'Shaughnessy KM, Fu B, Dickerson C, et al.: The gain-of-function G389R variant of the beta1-adrenoceptor does not influence blood pressure or heart rate response to beta-blockade in hypertensive subjects. Clin Sci (Lond) 2000, 99:233-238.
46. Jia H, Sharma F, Hopper R, et al.: beta2-adrenoceptor gene polymorphisms and blood pressure variations in East Anglian Caucasians. J Hypertens 2000, 18:687-693.
47. Kurland L, Melhus H, Karlsson J, et al.: Angiotensinogen gene polymorphisms: relationship to blood pressure response to antihypertensive treatment. Am J Hypertens 2004, 17:8-13.
48. Dudley C, Keavney B, Casadei B, et al.: Prediction of patient responses to antihypertensive drugs using genetic polymorphisms: investigation of renin-angiotensin system genes. J Hypertens 1996, 14:259-262.
49. Jia H, Hingorani AD, Sharma P, et al.: Association of the G(s)alpha gene with essential hypertension and response to beta-blockade. Hypertension 1999, 34:8-14.
50. Hingorani A, Jia H, Stevens P, et al.: Renin-angiotensin system gene polymorphisms influence blood pressure and the response to angiotensin converting enzyme inhibition. J Hypertens 1995, 13:1602-1609.
51. Li X, Du Y, Huang X: Correlation of angiotensin-converting enzyme gene polymorphism with effect of antihypertensive therapy by angiotensin-converting enzyme inhibitor. J Cardiovasc Pharmacol Therap 2003, 8:25-30.
52. Nakano Y, Oshima T, Watanabe M, et al.: Angiotensin I-converting enzyme gene polymorphism and acute response to captopril inessential hypertension. Am J Hypertens 1997, 10(9 Pt 1): 064-1068.
53. Ohmichi N, Iwai N, Uchida Y, et al.: Relationship between the response to the angiotensin converting enzyme inhibitor imidapril and the angiotensin converting enzyme genotype. Am J Hypertens 1997, 10:951-955.
54. Sasaki M, Oki T, Iuchi A, et al.: Relationship between the angiotensin converting enzyme gene polymorphism and the effects of enalapril on left ventricular hypertrophy and impaired diastolic filling in essential hypertension: M-mode and pulsed Doppler echocardiographic studies. J Hypertens 1996, 14:1403-1408.
55. Stavroulakis GA, Makris TK, Krespi PG, et al.: Predicting response to chronic antihypertensive treatment with fosinopril: the role of angiotensin-converting enzyme gene polymorphism. Cardiovasc Drug Ther 2000, 14:427-432.
56. Todd GP, Chadwick IG, Higgins KS, et al.: Relation between changes in blood pressure and serum ACE activity after a single dose of enalapril and ACE genotype in healthy subjects. Br J Clin Pharmacol 1995, 39:131-134.
57. Benetos A, Cambien F, Gautier S, et al.: Influence of the angiotensin II type 1 receptor gene polymorphism on the effects of perindopril and nitrendipine on arterial stiffness in hypertensive individuals. Hypertension 1996, 28:1081-1084.
58. Ortlepp JR, Hanrath P, Mevissen V, et al.: Variants of the CYP11B2 gene predict response to therapy with candesartan. Eur J Pharmacol 2002, 445:151-152.